SYMBIOTEC PHARMALAB LTD (SYMBIOTEC): SYMBIOTEC PHARMALAB Share Price Rises 5.83% Today to Rs 1,157
- September 21, 2026
- Posted by: Harsh Piplani
- Category: News
SYMBIOTEC Share Price moved higher today, closing at Rs 1,157 after a 5.83% rise from the previous close of Rs 1,093.25. The company’s market capitalisation stands at Rs 7,024.80 Cr, placing the move in clear market context for SYMBIOTEC Share Price Today watchers. The supplied data confirms the same-day price rise, but it does not establish a company-specific catalyst. For readers tracking SYMBIOTEC Stock News, the important near-term reference points are the day’s range of Rs 1,104.75 to Rs 1,157.95, turnover of Rs 4.81 Cr and the company’s current valuation. Univest is using only the verified figures supplied here to explain what changed, why the stock is in focus, and what investors can monitor next without making assumptions.
SYMBIOTEC Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,157 |
| Previous Close | Rs 1,093.25 |
| Today's Move | Rs 63.75 (+5.83%) |
| Open | Rs 1,105.9 |
| High | Rs 1,157.95 |
| Low | Rs 1,104.75 |
| Turnover | Rs 4.81 crore |
| Market Capitalisation | Rs 7,024.8 crore |
| Market Cap Category | Mid Cap |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) rose to Rs 1,157 from the previous close of Rs 1,093.25, a move of Rs 63.75 or 5.83%. The stock opened at Rs 1,105.9, reached a high of Rs 1,157.95, recorded a low of Rs 1,104.75.
SYMBIOTEC Share Price opened at Rs 1,105.90, traded between Rs 1,104.75 and Rs 1,157.95, and ended at Rs 1,157. The day’s gain of Rs 63.75 against the previous close of Rs 1,093.25 shows a firm close relative to the session’s opening level. Turnover came to Rs 4.81 Cr, which is a factual traded-value measure only. For SYMBIOTEC Share Price Today, the move is best read as a verified same-day rise rather than a stated explanation for why the stock moved. Univest notes the event, the exact price levels and the day’s percentage change, while leaving the cause unassigned because the supplied data does not identify one.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,024.8 crore |
| P/E Ratio | 63.92x |
| P/B Ratio | 4.73x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 231.19 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 63.92x, P/B 4.73x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7024.8 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 63.92x, P/B at 4.73x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 17.1, book value per share of Rs 231.19, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.87x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 63.92x |
| Benchmark Median P/E | 32.87x |
| Benchmark Average P/E | 48.77x |
| Benchmark P/E Range | 3.4x to 683.5x |
| Company P/B Ratio | 4.73x |
| Benchmark Median P/B | 3.08x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.46% |
| Company Market Capitalisation | Rs 7,024.8 crore |
| Benchmark Median Market Cap | Rs 701.78 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 63.92x, which is above the benchmark median of 32.87x, a difference of +94.46%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.7%, a difference of -4.1%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.46%, a difference of -7.8%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,40,397.93 | 36.41 | 5.09 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,48,664.42 | 85.01 | 14.08 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,82,738.23 | 83.79 | 20.36 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,012.19 | 25.48 | 4.27 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,10,793.75 | 32.87 | 3.15 | 11.83 | 16 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 63.92x compared with the displayed peer median of 36.41x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,024.8 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC
- SYMBIOTEC Share Price rose 5.83% today to Rs 1,157 from the previous close of Rs 1,093.25.
- The stock’s day range was Rs 1,104.75 to Rs 1,157.95, which frames the session’s price action clearly.
- Market capitalisation stands at Rs 7,024.80 Cr, giving a size reference for SYMBIOTEC Share Price Today.
- P/E is 63.92 and P/B is 4.73, both above the same-industry benchmark median.
- ROE is 11.22% and ROCE is 12.41%, which can be compared with the industry and peer figures.
About SYMBIOTEC
SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied dataset does not include a longer business description, so the company profile here remains focused on the verified market identity and financial context. For readers following SYMBIOTEC Company News, the listed business sits within a sector that is typically assessed through valuation, return ratios and peer comparison rather than through the day’s price move alone. The company is quoted on Indian stock market platforms through its NSE and BSE tracking context, and the current data set provides enough information to discuss its market capitalisation, earnings per share, book value and valuation multiples. Univest presents the company overview in a disciplined way: what is verified, what is measurable and what can be compared with the broader Pharmaceuticals & Drugs universe.
Track SYMBIOTEC Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Investors can track SYMBIOTEC Share Price on Univest for live share price updates, fundamental ratios, shareholding pattern, 52-week levels and market insights. The same page also helps users review SYMBIOTEC Share Price Today alongside valuation metrics such as P/E, P/B, ROE, ROCE, EPS and book value. For ongoing SYMBIOTEC Stock News monitoring, Univest keeps the discussion centred on verified data so readers can follow price action, sector context and peer comparison in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did SYMBIOTEC Share Price rise today?
Ans. SYMBIOTEC Share Price rose 5.83% today, but the supplied data does not establish a company-specific catalyst. The verified facts show the move, the closing price of Rs 1,157 and the market capitalisation of Rs 7,024.80 Cr.
What is SYMBIOTEC Share Price today?
Ans. SYMBIOTEC Share Price today is Rs 1,157. It was up Rs 63.75 from the previous close of Rs 1,093.25, and the stock traded within a day range of Rs 1,104.75 to Rs 1,157.95.
How much did SYMBIOTEC stock gain today?
Ans. SYMBIOTEC stock gained 5.83% in the session, which equals Rs 63.75. The move is a verified same-day price rise and should be read together with the turnover of Rs 4.81 Cr and the close of Rs 1,157.
What is the market cap of SYMBIOTEC?
Ans. SYMBIOTEC’s market capitalisation is Rs 7,024.80 Cr. That places it well above the industry median shown in the supplied benchmark, while remaining far below the industry average because the comparison set includes several much larger names.
Is SYMBIOTEC expensive compared with its industry?
Ans. SYMBIOTEC’s P/E of 63.92 is above the same-industry median of 32.87 and average of 48.77. Its P/B of 4.73 is also above the benchmark median of 3.08 and average of 4.31.
How do SYMBIOTEC’s returns compare with peers?
Ans. SYMBIOTEC reports ROE of 11.22% and ROCE of 12.41%. Those figures sit below several supplied peers, including Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals and Zydus Lifesciences, based on the numbers shown.
What do EPS and book value mean for SYMBIOTEC?
Ans. SYMBIOTEC’s EPS is Rs 17.10 and book value is Rs 231.19. EPS shows earnings attributable to each share, while book value per share shows the accounting net worth behind each share at the current point.
Does SYMBIOTEC pay a dividend?
Ans. The supplied dividend yield is 0, so no dividend yield is shown in this data set. Investors reading SYMBIOTEC Share Price should therefore rely on price action, valuation and return ratios rather than any current yield figure.
